3 days popular7 days popular1 month popular3 months popular

A New, Innovative Strategy For Assessing Concussion In Young Athletes

Concussion is a common disorder estimated to affect no fewer than 1.7-3.8 million people in the U.S. each year. Many more people with concussion likely do not seek medical care for symptoms of concussion and may suffer long-lasting, progressive, and profoundcognitive, psychiatric, and neurologic effects. The first use of teleconcussion, a novel solution for management and follow-up of a concussed athlete with remote access technology, is described in an article published in Telemedicine and e-Health, a peer-reviewed journal from , Inc., publishers. The article is available free on the Telemedicine and e-Health website.*

In the article “Teleconcussion: An Innovative Approach to Screening, Diagnosis, and Management of Mild Traumatic Brain Injury,”** Bert Vargas, MD and colleagues, Mayo Clinic Arizona–Neurology (Phoenix), present a case study in which telemedicine is used to assess and manage a high school athlete who had begun to resume physical activity following a concussion, in advance of accepted return-to-play guidelines. As in many states, Arizona law mandates that players of interscholastic sports removed from competitions for suspicion of having a concussion require formal clearance by a specially trained healthcare provider before returning to play. The use of telemedicine networks to facilitate timely access to subspecialty care can help ensure the health and safety of rural student-athletes.

“The ability to identify a mild traumatic brain injury (TBI) soon after it is sustained, whether on the battlefield or the sports field, is of great importance and high utility,” says , MBA, one of the Editors-in-Chief of the Journal and Research Professor of Family and Community Medicine, , . “The integration of ‘teleconcussion’ and Vargas et al.’s work can add great value to this very important field.”

Source

* http://www.liebertpub.com/tmj
** http://online.liebertpub.com/doi/full/10.1089/tmj.2012.0118
Mary Ann Liebert, Inc./Genetic Engineering News